Table 3.

Biomarker levels at 0, 6, and 24 hours

Urinary biomarker	Time measured (h)	Early death	AKD	Early reversal	P value 3 groups	P value 2 groupsa
TIMP-2∗IGFBP7, (ng/ml)2/1000	0	1.32 (0.30–3.91) n = 78	1.48 (0.39–5.28) n = 108	1.12 (0.29–2.93) n = 239	0.23	0.11
	6	1.69 (0.30–4.33) n = 79	1.31 (0.34–3.38) n = 126	0.49 (0.17–1.60) n = 263	<0.001	<0.001
	24	1.63 (0.48–5.01) n = 62	0.59 (0.17–1.92) n = 129	0.36 (0.13–1.08) n = 264	<0.001	0.003
NGAL, ng/ml	0	331.7 (117.3–577.6) n = 12	465.2 (14.7–629.5) n = 11	332.9 (38.4–629.5) n = 42	0.95	0.93
	6	897.9 (130.6–2098.4) n = 21	1907.4 (391.6–2098.4) n = 47	714.4 (161.6–2098.4) n = 82	0.04	0.01
	24	1168.0 (414.9–2098.4) n = 21	1244.3 (365.8–2098.4) n = 47	613.6 (117.7–2098.4) n = 82	0.11	0.09
KIM-1, pg/ml	0	1.50 (0.76–4.84) n = 36	1.30 (0.70–3.70) n = 47	1.30 (0.40–2.80) n = 123	0.21	0.16
	6	1.60 (0.90–4.77) n = 34	1.30 (0.58–3.54) n = 59	1.00 (0.50–3.61) n = 130	0.08	0.63
	24	1.82 (0.78–5.36) n = 30	1.33 (0.40–3.46) n = 59	1.20 (0.50–3.09) n = 125	0.30	0.99
L-FABP, pg/ml	0	73.6 (44.2–1779.0) n = 16	49.8 (16.9–155.4) n = 27	89.4 (15.9–247.8) n = 61	0.39	0.65
	6	187.3 (92.90–2121.6) n = 11	54.1 (16.9–145.3) n = 29	77.3 (19.8–165.8) n = 66	0.04	0.64
	24	52.5 (25.6–4552.8) n = 10	45.4 (20.5–138.9) n = 29	56.8 (13.8–117.6) n = 66	0.72	0.84
Type IV collagen, mcg/L	0	13.02 (7.31–36.85) n = 33	23.94 (5.11–69.68) n = 44	13.93 (5.30–27.05) n = 116	0.34	0.14
	6	22.27 (12.65–58.90) n = 32	22.55 (9.23–82.59) n = 56	14.10 (6.10–41.6) n = 122	0.048	0.13
	24	26.93 (15.87–71.84) n = 28	23.89 (8.09–71.58) n = 56	21.72 (9.17–40.94) n = 117	0.49	0.45

AKD, acute kidney disease; IGFBP7, insulin-like growth factor-binding protein 7; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid binding protein; NGAL, neutrophil gelatinase-associated lipocalin; TIMP-2, tissue inhibitor of metalloproteinases-2.

Data shown as median (interquartile range).

^aP value for AKD compared with early-reversal groups.